Extended Data Fig. 2: Her2-targeted therapies induce ROS in breast cancer cells. | Nature Metabolism

Extended Data Fig. 2: Her2-targeted therapies induce ROS in breast cancer cells.

From: NRF2 activation promotes the recurrence of dormant tumour cells through regulation of redox and nucleotide metabolism

Extended Data Fig. 2

a, DCFDA staining showing ROS levels in mammospheres cultured with dox or without dox for 2 days. Significance was determined by two-sided Student’s t test, and data are represented as mean ± SEM (n = 6 fields of view). Scale bars represent 100μm. b, DCFDA staining showing ROS levels in MDA-MB-231 cells treated with 500 nM lapatinib for 48 hours. Data are representative of n = 3 biologically independent replicates for a single experiment. c, DCFDA staining showing ROS levels in SKBR3, BT474, and MDA-MB-231 cells treated with 500 nM neratinib for 48 hours. Data are shown as the mean ± SEM for n = 3 biologically independent replicates for a single experiment. Significance was determined by two-sided Student’s t test.

Back to article page